#OphthalmologyInnovation

Great news from BRIM Biotechnology, Inc. (6885.TWO)! The company has announced its three focus areas for this year's operations, which include:

1. Continuing the development of BRM421, their lead asset of treatment for dry eye disease (#DED), with unwavering determination.
2. Advancing the progress of the second Phase III clinical studies unaffected by the previous setback.
3. Enhancing its pipeline through mergers and acquisitions, licensing, and incubation of new technology by collaborations.

Andrew Lin, Chairman of the Board, revealed that BRIM Biotechnology received complete data from the Phase III clinical study of BRM421 on January 16th. A comprehensive analysis report is expected by mid-May.

Despite the setback in the unblinding of the Phase III study of BRM421 at the end of last year, the initial results have sparked several ideas within the company. This includes efforts to enhance drug concentration, explore new excipients, or extend drug treatment duration.

You can read more about this exciting update by following this link:
https://lnkd.in/gB24Md4u

Stay tuned for more updates and innovations in ophthalmology with #Globalbio!